Skip to main content

Day: December 2, 2020

One Liberty Properties, Inc. Announces Cash Dividend

GREAT NECK, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP) today announced that its Board of Directors declared a quarterly cash dividend for the Company’s common stock of $0.45 per share. The dividend is payable on January 7, 2021 to stockholders of record as of December 17, 2020. The Company expects that this dividend will be included in 2021 taxable income.Contact:One Liberty PropertiesInvestor RelationsPhone: (516) 466-3100www.onelibertyproperties.com

Continue reading

DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 30 NOVEMBER 2020

French public limited company (société anonyme)with a share capital of €1,533,798,045.00Registered office : 1, cours Ferdinand de Lesseps92500 Rueil-Malmaison – France552 037 806 RCS Nanterrewww.vinci.comDISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS  AS OF 30 NOVEMBER 2020This disclosure is on VINCI web site www.vinci.com (section investors/financial information/regulatory information/7. monthly information concerning the total number of voting rights and shares that make up the company’s capital).Attachment2020 11 30 ddv English version

Continue reading

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 30 NOVEMBRE 2020

Société anonyme au capital de 1 533 798 045,00 €Siège social : 1, cours Ferdinand de Lesseps92500 Rueil-Malmaison – France552 037 806 RCS Nanterrewww.vinci.comDECLARATIONDU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTEAU 30 NOVEMBRE 2020Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMFCatégorie de titres : actions ordinaires (ISIN : FR0000125486)Cette déclaration est en ligne sur le site internet de VINCI www.vinci.com(rubrique : investisseurs/information financière/information réglementée/7. l’information mensuelle relative au nombre total de droits de vote et d’actions composant le capital de la société).Pièce jointe2020 11 30 ddv vers en français

Continue reading

Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate

 Phase 2 study VLA15-221 planned to be initiated in Q1 2021, subject to regulatory approvalFirst clinical study of VLA15 that includes a pediatric population, aged 5-17 yearsStudy will include participants from 5-65 years of age and a reduced immunization schedule (Month 0-6 compared to Month 0-2-6)The study will trigger a milestone payment, upon dosing of the first subject, from Pfizer to Valneva of $10 millionPhase 3 pivotal efficacy trial is planned to commence in 2022Saint-Herblain (France), December 2, 2020 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced its plans to accelerate pediatric development of its Lyme vaccine candidate, VLA15, in collaboration with Pfizer Inc. (NYSE: PFE), with the planned initiation of study VLA15-221 in the first quarter of...

Continue reading

Valneva annonce l’accélération du développement pédiatrique de son candidat vaccin contre la maladie de Lyme

Etude de Phase 2 VLA15-221 prévue pour être initiée au T1 2021, sous réserve de l’approbation des autorités réglementairesPremière étude de VLA15 incluant une population pédiatrique, âgée de 5 à 17 ansL’étude portera sur des participants âgés de 5 à 65 ans et un calendrier de vaccination plus court (vaccination à 0 et 6 mois contre 0, 2 et 6 mois précédemment)La vaccination du premier participant à cette étude déclenchera un paiement d’étape de Pfizer à Valneva s’élevant à 10 millions de dollarsLe lancement de l’étude pivot d’efficacité de Phase 3 est prévu en 2022Saint-Herblain (France), 2 décembre 2020 – Valneva SE (“Valneva”), société spécialisée dans les vaccins contre des maladies générant d’importants besoins médicaux, a annoncé aujourd’hui son intention d’accélérer le développement pédiatrique de son vaccin contre la maladie de...

Continue reading

COFACE SA : Déclaration du nombre total des droits de vote et du nombre d’actions composant le capital social au 30 novembre 2020

Paris, le 2 décembre 2020 – 17h45COFACE SA : Déclaration du nombre total des droits de vote et du nombre d’actions composant le capital social au 30 novembre 2020y compris actions auto-détenuesdéduction faite des actions auto-détenuesPièce jointe2020 11 30 Declaration Actions&Droits de Vote FR

Continue reading

Manutan Group : 2019/2020 financial year : Good resilience of the Manutan Group in an economic context severely disrupted by the health crisis : A turnover in slight growth and profitability preserved

 Financial notice of December 2nd 20202019/2020 financial year :Good resilience of the Manutan Group in an economic context severely disrupted by the health crisis :A turnover in slight growth and profitability preservedReturn to growth in the Q4 (July – September 2020)Compared to the 2018/2019 financial year, the Group continues to grow and registers an increase of +0.8% (-1.6% at constant scope, exchange rates and number of working days). After having experienced a strong negative impact linked to the Covid-19 crisis in March and April, the Group returned to growth from May, with an increase in turnover of +3.8% for the period from May to September (+3.0% at constant scope, exchange rates and number of working days).Current operating profit above 7% of TurnoverOver the 2019/2020 financial year, current operating profit represents 7.5%...

Continue reading

Manutan Group : Exercice 2019/2020 : Bonne résilience du Groupe Manutan dans un contexte économique très perturbé par la crise sanitaire :Un chiffre d’affaires en légère croissance et une rentabilité préservée

Avis financier du 02 décembre 2020Exercice 2019/2020 :Bonne résilience du Groupe Manutan dans un contexte économique très perturbé par la crise sanitaire :Un chiffre d’affaires en légère croissance et une rentabilité préservéeRetour de la croissance lors du 4ème trimestre (Juillet – Septembre 2020)L’activité du Groupe est en croissance de +0,8% sur l’ensemble de l’exercice 2019/2020 (-1,6% à périmètre, change et jours constants). Après avoir connu un fort impact négatif lié à la crise du Covid-19 sur les mois de mars et avril, le Groupe renoue avec la croissance dès le mois de mai, avec une progression du chiffre d’affaires de +3,8% pour la période de mai à septembre (+3,0% à périmètre, change et jours constants).Une rentabilité opérationnelle courante supérieure à 7% du chiffre d’affairesLa rentabilité opérationnelle courante s’établit...

Continue reading

SOLUTIONS 30 EXPANDS INTO THE UNITED KINGDOM

Solutions 30 Group announced today that it has signed a deal to acquire 100% of Comvergent Holdings Limited (Comvergent). This transaction marks the entry of Solutions 30 into the UK market, which has strong development potential in the field of fixed and mobile telecommunications. In 2019, Comvergent had sales close to €17.5 million. The company will be fully consolidated in Solutions 30 Group’s financial statements as from December 1, 2020.Founded in 2005, Comvergent has developed a range of multi-technical services dedicated to rolling out and maintaining wireless networks. Based near Chester in North West England, the company operates throughout the United Kingdom with a team of technicians spread across the country. Comvergent has been working for more than 10 years with major telecom equipment manufacturers, including Ericsson,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.